Management ChangeJul 8, 2026, 04:06 PM
Candel Therapeutics Appoints Mark Sims as CCO, Grants Stock Options
AI Summary
Candel Therapeutics, Inc. announced the appointment of Mark Sims as its new Chief Commercial Officer, effective July 6, 2026. In connection with his employment, the Compensation Committee granted Mr. Sims inducement stock options to purchase an aggregate of 285,000 shares of common stock. The options have an exercise price of $10.03 per share and will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.
Key Highlights
- Candel Therapeutics appointed Mark Sims as Chief Commercial Officer.
- Granted Mr. Sims stock options to purchase 285,000 shares.
- Exercise price set at $10.03 per share.
- Options vest 25% on first anniversary, then monthly over 36 months.
- Award made under the Company's 2025 Inducement Plan.
Price Impact
More from CADL